{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:43:11Z","timestamp":1792806191626,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,9,7]],"date-time":"2027-09-07T00:00:00Z","timestamp":1820275200000},"content-version":"am","delay-in-days":341,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA262804"],"award-info":[{"award-number":["R01CA262804"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ygyno.2026.08.016","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T21:46:40Z","timestamp":1788817600000},"page":"33-40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Mutated p53 results in altered type I interferon pathway expression and signaling in endometrial cancer"],"prefix":"10.1016","volume":"213","author":[{"given":"Annalyn M.","family":"Welp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex R.","family":"Mabry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caleb L.","family":"Lines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Premal H.","family":"Thaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Mutch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary M.","family":"Mullen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason D.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2026.08.016_bb0005","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2026.08.016_bb0010","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1136\/ijgc-2020-002256","article-title":"p53abn endometrial Cancer: understanding the most aggressive endometrial cancers in the era of molecular classification","volume":"31","author":"Jamieson","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2026.08.016_bb0015","first-page":"67","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Levine","year":"2013","journal-title":"Nature Nature Publishing Group"},{"key":"10.1016\/j.ygyno.2026.08.016_bb0020","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bjc.2015.190","article-title":"A clinically applicable molecular-based classification for endometrial cancers","volume":"113","author":"Talhouk","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2026.08.016_bb0025","series-title":"Uterine Neoplasms [Internet]","author":"NCCN","year":"2026"},{"key":"10.1016\/j.ygyno.2026.08.016_bb0030","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1200\/JCO.21.02506","article-title":"TP53 sequencing and p53 immunohistochemistry predict outcomes when bevacizumab is added to frontline chemotherapy in endometrial Cancer: an NRG oncology\/gynecologic oncology group study","volume":"40","author":"Thiel","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.08.016_bb0035","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41568-023-00658-3","article-title":"Translating p53-based therapies for cancer into the clinic","volume":"24","author":"Peuget","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ygyno.2026.08.016_bb0040","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ccell.2021.01.003","article-title":"Mutant p53 suppresses innate immune signaling to promote tumorigenesis","volume":"39","author":"Ghosh","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ygyno.2026.08.016_bb0045","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1084\/jem.20080383","article-title":"Transcriptional role of p53 in interferon-mediated antiviral immunity","volume":"205","author":"Mu\u00f1oz-Fontela","year":"2008","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ygyno.2026.08.016_bb0050","article-title":"Elevated type I interferon signaling defines the proliferative advantage of ARF and p53 mutant tumor cells [internet]","author":"Mabry","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.ygyno.2026.08.016_bb0055","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/nature01850","article-title":"Integration of interferon-\u03b1\/\u03b2 signalling to p53 responses in tumour suppression and antiviral defence","volume":"424","author":"Takaoka","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2026.08.016_bb0060","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41392-024-01765-9","article-title":"Harnessing innate immune pathways for therapeutic advancement in cancer","volume":"9","author":"Hu","year":"2024","journal-title":"Sig. Transduct. Target. Ther."},{"key":"10.1016\/j.ygyno.2026.08.016_bb0065","doi-asserted-by":"crossref","unstructured":"Chadwick TB, So J, Hertzog PJ, Haynes NM, Parker BS. Striking the right balance with type I interferon signalling in cancer. Nat. Rev. Cancer Nature Publishing Group; 2026;1\u201324.","DOI":"10.1038\/s41568-026-00915-1"},{"key":"10.1016\/j.ygyno.2026.08.016_bb0070","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.18632\/oncotarget.679","article-title":"Reactivation of codogenic endogenous retroviral (ERV) envelope genes in human endometrial carcinoma and prestages: emergence of new molecular targets","volume":"3","author":"Strissel","year":"2012","journal-title":"Oncotarget"},{"key":"10.1016\/j.ygyno.2026.08.016_bb0075","doi-asserted-by":"crossref","unstructured":"Powell MA, Auranen A, Willmott LJ, Gilbert L, Black D, Cibula D, et al. 37MO Dostarlimab plus chemotherapy in primary advanced or recurrent endometrial cancer (pA\/rEC) in the RUBY trial: overall survival (OS) by MMR status and molecular subgroups. ESMO Open [Internet]. Elsevier; 2024 [cited 2026 Apr 17];9. Available from: https:\/\/www.esmoopen.com\/article\/S2059-7029(24)01306-1\/fulltext.","DOI":"10.1016\/j.esmoop.2024.103537"},{"key":"10.1016\/j.ygyno.2026.08.016_bb0080","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1158\/1078-0432.CCR-18-3241","article-title":"Molecular subtype not immune response drives outcomes in endometrial carcinoma","volume":"25","author":"Talhouk","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2026.08.016_bb0085","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1158\/2326-6066.CIR-20-0149","article-title":"Prognostic integrated image-based immune and molecular profiling in early-stage endometrial cancer","volume":"8","author":"Horeweg","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ygyno.2026.08.016_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2024.07.001","article-title":"A toolkit for a modern gynecologic oncology tissue bank","volume":"189","author":"Graham","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.08.016_bb0095","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1158\/1078-0432.CCR-24-2200","article-title":"HMGA2 expression predicts subtype, survival, and treatment outcome in pancreatic ductal adenocarcinoma","volume":"31","author":"Yamamoto","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2026.08.016_bb0100","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1101\/gr.1239303","article-title":"Cytoscape: a software environment for integrated models of biomolecular interaction networks","volume":"13","author":"Shannon","year":"2003","journal-title":"Genome Res."},{"key":"10.1016\/j.ygyno.2026.08.016_bb0105","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1093\/nar\/gkv1507","article-title":"TCGAbiolinks: an R\/Bioconductor package for integrative analysis of TCGA data","volume":"44","author":"Colaprico","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ygyno.2026.08.016_bb0110","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.cell.2020.01.026","article-title":"Proteogenomic characterization of endometrial carcinoma","volume":"180","author":"Dou","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ygyno.2026.08.016_bb0115","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The molecular signatures database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst."},{"key":"10.1016\/j.ygyno.2026.08.016_bb0120","doi-asserted-by":"crossref","first-page":"42716","DOI":"10.18632\/oncotarget.8446","article-title":"The biology of DHX9 and its potential as a therapeutic target","volume":"7","author":"Lee","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.ygyno.2026.08.016_bb0125","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1158\/2767-9764.CRC-23-0488","article-title":"Induction of viral mimicry upon loss of DHX9 and ADAR1 in breast cancer cells","volume":"4","author":"Cottrell","year":"2024","journal-title":"Cancer Res Commun"},{"issue":"5","key":"10.1016\/j.ygyno.2026.08.016_bb0130","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","article-title":"High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types","volume":"32","author":"McGrail","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2026.08.016_bb0140","doi-asserted-by":"crossref","first-page":"A25","DOI":"10.1136\/ijgc-2024-ESGO.32","article-title":"625 Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer: analysis of progression-free survival and overall survival outcomes by molecular classification in the ENGOT-EN6-NSGO\/GOG-3031\/RUBY trial","volume":"34","author":"Mirza","year":"2024","journal-title":"Int. J. Gynecol. Cancer. Elsevier"},{"key":"10.1016\/j.ygyno.2026.08.016_bb0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024855","article-title":"The role of PKR\/eIF2\u03b1 signaling pathway in prognosis of non-small cell lung Cancer","volume":"6","author":"He","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2026.08.016_bb0150","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/sj.onc.1202293","article-title":"Cell cycle regulation of the double stranded RNA activated protein kinase, PKR","volume":"18","author":"Zamanian-Daryoush","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.ygyno.2026.08.016_bb0155","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1128\/MCB.19.7.4653","article-title":"Induction of apoptosis by double-stranded-RNA-dependent protein kinase (PKR) involves the \u03b1 subunit of eukaryotic translation initiation factor 2 and NF-\u03baB","volume":"19","author":"Gil","year":"1999","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.ygyno.2026.08.016_bb0160","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s41379-022-01102-x","article-title":"p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial","volume":"35","author":"Vermij","year":"2022","journal-title":"Mod. Pathol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.08.016_bb0165","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ccell.2025.12.002","article-title":"Targeting STING to generate therapeutic anti-tumor immunity","volume":"44","author":"Fahey","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ygyno.2026.08.016_bb0170","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ygyno.2024.12.003","article-title":"Palbociclib plus letrozole in estrogen receptor-positive advanced\/recurrent endometrial cancer: double-blind placebo-controlled randomized phase II ENGOT-EN3\/PALEO trial","volume":"192","author":"Mirza","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.08.016_bb0175","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1545038","article-title":"Onvansertib exhibits anti-proliferative and anti-invasive effects in endometrial cancer","volume":"16","author":"Sinha","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ygyno.2026.08.016_bb0180","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-25-1196","article-title":"DHX9 inhibition enhances paclitaxel sensitivity by inducing mitotic failure in ovarian and endometrial cancers","author":"Huang","year":"2026","journal-title":"Mol. Cancer Ther."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826021086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826021086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:13:57Z","timestamp":1792804437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825826021086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":35,"alternative-id":["S0090825826021086"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.08.016","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mutated p53 results in altered type I interferon pathway expression and signaling in endometrial cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.08.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}